None of the 24 patients diagnosed with ITP with suggestive COVID-19 developed thrombotic events during the infection despite the fact that four had been administered thrombopoietin receptor agonists (TPO-RA), six had been splenectomised, and seven had other prothrombotic risk factors. This evidence concerns the gene MPL and COVID-19.